<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03215446</url>
  </required_header>
  <id_info>
    <org_study_id>STEINBERG-GIRARD 2015</org_study_id>
    <nct_id>NCT03215446</nct_id>
  </id_info>
  <brief_title>Evaluate the Muscle Protection Effect of Sevoflurane Sedation in Vascular Surgery</brief_title>
  <acronym>PHAR</acronym>
  <official_title>Evaluation of Total (Pre and Post) Conditioning on Rhabdomyolysis of Sedation With Sevoflurane Versus Propofol in Vascular Surgery With Clamping</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Dijon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Dijon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Halogenated anaesthetic agents (HAA) may induce protective processes by pre-conditioning the
      myocardium. All of the literature shows that HAA induce pre-conditioning, thanks to a class
      effect, and Sevoflurane is the most widely used today.

      In humans, the protective effects of halogenated agents have principally been studied in
      heart surgery and have shown encouraging clinical results. It seems that HAA induce both
      pre-conditioning of the myocardium (early and late) and post conditioning.

      Given these protective effects of HAA, in 2007, the American Heart Association (AHA)
      recommended the use of HAA for anaesthesia maintenance in non-cardiac surgery in patients
      with a high cardio-vascular risk. The aim of this study is to show a decrease in
      rhabdomyolysis and tissue distress (kidneys, myocardium and liver), thanks to Sevoflurane
      anaesthesia, in the post-operative period following vascular surgery with clamping
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 13, 2016</start_date>
  <completion_date type="Anticipated">December 13, 2018</completion_date>
  <primary_completion_date type="Anticipated">June 13, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change from baseline Creatine PhosphoKinase</measure>
    <time_frame>up to 24 hours post surgery</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">164</enrollment>
  <condition>Vascular Surgery</condition>
  <arm_group>
    <arm_group_label>propofol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>sevoflurane</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>maintenance of anaesthesia with propofol</intervention_name>
    <arm_group_label>propofol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>maintenance of anaesthesia with sevoflurane</intervention_name>
    <arm_group_label>sevoflurane</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  persons who have provided written consent

          -  patients over 18 years of age

          -  patients undergoing scheduled vascular surgery with high clamping for:

               -  Abdominal aortic aneurysm

               -  suprapopliteal vascular bypass (aorto-bi-femoral, femoral trifurcation,
                  ilio-femoral or femoro-femoral, femoro-popliteal).

        Exclusion Criteria:

          -  persons without health insurance cover

          -  patients younger than 18 years of age, pregnant or breast-feeding women and adults
             under guardianship

          -  patients with epilepsy

          -  emergency surgery

          -  patient presenting a contra-indication for Sevoflurane: hypersensitivity to
             sevoflurane or to other halogenated anaesthetic agents, myopathy, hyper-eosinophilia,
             immunoallergic hepatitis, known or suspected genetic predisposition to malignant
             hyperthermia

          -  patients presenting a contra-indication to the use of Propofol: known hypersensitivity
             to propofol or to one of the constituents of the product, allergy to peanuts or soja

          -  Patients presenting a contra-indication for sufentanil: hypersensitivity to sufentanil
             or to opioids

          -  Association with opioid agonists-antagonists or partial opioid antagonists

          -  patients presenting a CI for the use of Cisatracurium: history of allergy or
             hypersensitivity to cisatracurium or atracurium

          -  patients presenting cardiac, respiratory, renal or kidney failure, hypovolemia, poor
             general health

          -  Patients with a risl of prolongation of the QT interval

          -  Patients with end-stage renal failure - requiring dialysis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Claude GIRARD</last_name>
    <phone>3.80.29.35.28</phone>
    <phone_ext>+33</phone_ext>
    <email>claude.girard@chu-dijon.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU dijon Bourgogne</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claude GIRARD</last_name>
      <phone>3.80.29.35.28</phone>
      <phone_ext>+33</phone_ext>
      <email>claude.girard@chu-dijon.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 26, 2017</study_first_submitted>
  <study_first_submitted_qc>July 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 12, 2017</study_first_posted>
  <last_update_submitted>July 10, 2017</last_update_submitted>
  <last_update_submitted_qc>July 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Sevoflurane</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

